Johnson & Johnson may be changing how pharmaceutical companies think about launch success. Its psoriasis treatment, Icotyde (icotrokinra), is attracting patients who have never received systemic therapy. According to J&J, roughly 60% of patients starting Icotyde are new to this treatment category rather than switching from competing systemic drugs. That raises an important question for pharmaceutical marketers: Should success depend on taking market share, or on bringing more eligible patients into treatment? The answer could change how drugmakers measure launch performance.
Table of Contents
- Why Icotyde’s Launch Numbers Matter
- Pharma Category Expansion Versus Market Share
- How Pharmaceutical Marketers Can Reach Untreated Patients
- Measuring Category Growth as a Commercial Outcome
- Conclusion
- Frequently Asked Questions
Why Icotyde’s Launch Numbers Matter
Johnson & Johnson’s Icotyde received FDA approval in March 2026. The once-daily oral treatment targets the interleukin-23 receptor and is approved for eligible patients with moderate-to-severe plaque psoriasis.
Unlike injectable biologics, Icotyde offers a targeted oral treatment option. Consequently, its launch has attracted attention beyond its clinical results.
During J&J’s October 2026 earnings call, executives reported that more than 20,000 patients had started Icotyde through nearly 9,000 prescribers. More importantly, approximately 60% of those patients had never received systemic psoriasis therapy.
Of the remaining 40%, roughly half came from other oral treatments, while the rest were thought to have switched from treatments such as biologics.
These figures suggest that Icotyde’s early growth involves more than conventional brand switching. Instead, a substantial portion of its adoption comes from patients entering the systemic treatment category for the first time.
However, these patients were not necessarily new to psoriasis care. Some may have previously relied on topical medications or other approaches that did not involve systemic treatment.
That distinction matters because it reveals a commercial opportunity beyond competing for existing prescriptions.
As J&J executives explained during the company’s third-quarter 2026 earnings discussion, early prescribing patterns point toward growth in the broader systemic treatment market.
Pharma Category Expansion Versus Market Share
Pharmaceutical companies traditionally measure launch success through prescription growth, market share, physician adoption, and conversions from competing brands.
These metrics remain valuable. However, they often overlook patients who have not yet entered a particular treatment category.
But there’s another way to measure success: looking at whether a new treatment brings more eligible patients into the market.
In practical terms, pharma category expansion means growing the number of eligible patients receiving appropriate treatment, rather than simply shifting prescriptions between competing brands.
For example, consider two psoriasis launches. One gains 10,000 patients primarily by switching them from competing systemic therapies. Another gains the same number, but most patients have never received systemic treatment.
Both launches generate prescriptions. Yet the second may also increase the number of patients participating in the systemic treatment market.
This difference could influence long-term category growth, physician engagement, and future treatment demand.
However, attracting patients who are new to systemic therapy does not automatically prove that a manufacturer expanded the overall market. Some might have started another systemic treatment even without the new product.
Therefore, marketers must distinguish between reaching previously untreated patients and creating genuinely additional demand.
Icotyde provides an interesting example because its early patient mix creates a reason to investigate that distinction.
Ultimately, market share measures competitive position, while category growth examines whether more eligible patients are receiving treatment.
How Pharmaceutical Marketers Can Reach Untreated Patients
For pharmaceutical launch teams, eligible patients who have not entered the systemic treatment market represent an important audience. However, reaching them requires a different strategy from persuading established patients to switch brands.
Identify Barriers Along the Psoriasis Treatment Journey
Some patients continue using topical treatments despite persistent symptoms. Others may hesitate to discuss additional options because of concerns about side effects, administration, cost, or insurance coverage.
Therefore, effective pharmaceutical marketing must begin by understanding the barriers that keep eligible patients from discussing systemic treatment.
Educational campaigns can explain when a conversation about additional treatment options may be appropriate.
Meanwhile, physician education can help clinicians identify patients whose symptoms or treatment experiences warrant reassessment.
The goal should never be to encourage unnecessary prescribing. Instead, responsible communications should support informed discussions between patients and healthcare professionals.
This patient-centered approach also reflects a broader shift in pharmaceutical marketing, where understanding individual treatment journeys is becoming as important as promoting product features.
Build Awareness Beyond Existing Brand Customers
Traditional competitive campaigns frequently target physicians who already prescribe advanced therapies.
However, growing the treatment market may require greater attention to clinicians who manage psoriasis patients before systemic therapy becomes part of the discussion.
Dermatology education, condition-specific search content, and carefully targeted digital engagement can help address this gap.
Additionally, marketers should consider the patient’s full journey, including diagnosis, treatment discussions, insurance approvals, and prescription initiation.
A patient who understands the available options may still face practical barriers to starting treatment.
As a result, awareness campaigns should connect with appropriate access and support resources.
For launch teams, the opportunity is to support informed treatment decisions rather than simply generate more advertising impressions.
Measuring Category Growth as a Commercial Outcome
If drugmakers want to measure how much they’re growing the treatment market, they’ll need to look beyond prescriptions and market share.
First, teams should track the percentage of new patients who have never received systemic treatment.
Next, they should examine how many eligible patients begin systemic therapy across the broader market, not just within one brand.
Useful performance indicators include:
- The percentage of patients starting systemic therapy for the first time
- Growth in the total number of patients receiving systemic treatment
- Time between treatment eligibility assessment and treatment initiation
- Prescriber adoption among clinicians with limited previous systemic prescribing
- Patient access barriers and treatment continuation rates
However, these measures require careful interpretation.
A rising share of patients new to systemic treatment could reflect genuine market growth, differences in patient recruitment, or changes in prescribing patterns.
Therefore, companies should compare launch data against historical treatment trends and relevant market benchmarks.
Claims data, longitudinal patient information, and physician research can provide additional context when collected and analyzed appropriately.
Furthermore, marketers should evaluate whether newly treated patients remain on appropriate therapy and experience meaningful clinical outcomes.
The FDA’s Icotyde clinical trial overview provides useful context about the approved treatment population and the clinical evidence supporting the therapy.
Ultimately, the strongest launch evaluations connect commercial growth with responsible patient access and treatment use.
Conclusion
J&J’s early Icotyde results raise an important question about pharmaceutical launch strategy.
If roughly 60% of patients are entering systemic psoriasis treatment for the first time, competitive switching tells only part of the commercial story.
For launch teams, that means looking beyond market share and asking a bigger question: Is the brand simply winning patients from competitors, or helping grow the overall treatment market?
However, proving that growth requires more than counting patients who are new to systemic therapy. Companies must determine whether their launches are increasing appropriate treatment initiation across the broader market.
For pharmaceutical marketers, the lesson is clear: Winning existing patients matters, but helping eligible patients enter appropriate care may represent an equally important opportunity.
Frequently Asked Questions
1. What is pharma category expansion?
It refers to growth in the overall market for a treatment category, including appropriate treatment initiation among eligible patients who previously did not use that type of therapy.
2. Why is Icotyde’s launch important for pharmaceutical marketers?
J&J reports that approximately 60% of early Icotyde patients were new to systemic psoriasis therapy. This highlights the potential importance of first-time treatment initiation alongside competitor conversion.
3. How does category expansion differ from market share growth?
Market share measures a brand’s portion of an existing market. Category expansion examines whether the total treatment market is growing, including through additional eligible patients starting treatment.
4. How can pharma companies measure treatment market growth?
Companies can analyze first-time systemic treatment initiations, overall category patient growth, prescribing patterns, and access data. Comparing results with historical trends helps determine whether growth is truly incremental.
5. Can reaching previously untreated patients improve long-term pharmaceutical growth?
Potentially. Helping additional eligible patients access appropriate treatment may support sustainable market growth. However, lasting success also depends on clinical outcomes, access, treatment continuation, and responsible prescribing.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
